0JQ2.LSE KALA BIO, Inc.

Healthcare Biotechnology London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-70.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0JQ2.LSE undervalued?

Graham number

The Graham number of KALA BIO, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

KALA BIO, Inc. fundamental analysis

No fundamental analysis for KALA BIO, Inc. yet.

KALA BIO, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About KALA BIO, Inc.

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC…

Full company profile